Children#s Lives Will be Saved Due to Invention of Simple Water Treatment System Aquatabs Flo

Food and Healthcare Press Releases Tuesday September 3, 2019 08:00
WEXFORD, Ireland--3 Sep--PRNewswire/InfoQuest
The world famous medical journal The Lancet has published the results of a two year health impact trial in Bangladesh. Less than 5% of studies submitted to this peer reviewed journal are published.

In this trial, the impact of using "Aquatabs Flo" at the inlet of a domestic tank water treatment system has been shown to reduce WHO-defined diarrhoea in children by over 25% compared to the control group (untreated water). Similar reductions were estimated for caregiver-defined diarrhoea.

The study also noted some other significant points:
  • "Previous blinded trials of household water treatment interventions in low-income settings have failed to detect a reduction in child diarrhoea".
  • "Previous water intervention trials have focused on household- level water treatment, (the) findings show that a low-cost automatic point-of-collection (community-level) water treatment intervention can achieve high uptake and reduce diarrhoea in a densely populated setting"
  • (The study) "detected significant improvements in stored household drinking water in the treatment group compared with the control group"

Overall, the study interpreted the results of this trial to mean that, "Passive chlorination at the point of collection could be an effective and scalable strategy in low-income urban settings for reducing child diarrhoea and for achieving global progress towards Sustainable Development Goal 6.1 to attain universal access to safe and affordable drinking water."

Commenting on the result of the trial Mr. Michael Gately MD of Aquatabs said, "Under the very toughest conditions in Bangladesh, this system has now been proven beyond doubt and children's lives Will be saved. It is the World's lowest-cost, automatic, no power required, tank water treatment system."

Mr Gately went on to say that Aquatabs Flo has now been installed in domestic water tanks in over 20,000 schools in Kenya & Nigeria by the social enterprise "Impact Water" with a confirmed target of over 40,000 schools by end of year 2019. Some 10 million children now have safe water with over 2 billion litres being treated per month.

Given the unprecedented results of this study, and subsequent success of the project rollout, the team at Aquatabs now seek further partners internationally, both from the NGO and Commercial communities for installation of this life changing system in water tanks of private homes throughout the Worlds emerging communities.

REF:
The Lancet:
https://www.thelancet.com/journals/langlo/article/PIIS2214-109X(19)30315-8/fulltext
Aquatabs Flo:
http://www.aquatabs.com/home/product-range/aquatabs-flo
Stanford University:
https://woods.stanford.edu/news/fighting-child-killer
The World Bank:
https://www.worldbank.org/en/programs/sief-trust-fund
Photo - https://mma.prnewswire.com/media/968093/The_Lancet.jpg
Logo - https://mma.prnewswire.com/media/968092/Aquatabs_Flo_Logo.jpg
Contact:
Declan Lee
Aquatabs Business Development Director
+353-87-369-9141
Declan.lee@kersia-group.com

Latest Press Release

Menarini: Elcin Barker Ergun Group CEO

"Elcin Barker Ergun is the ideal addition to the Menarini team, in order to continue the agenda of growth in geography and therapeutic areas," commented Eric Cornut, Chairman of Menarini. Elcin Barker Ergun: "Menarini is a company admired on a global...

Strekin AG Announces Completion of Patient Recruitment in the RESTORE Phase 3 Clinical Study of STR001

Strekin AG (www.strekin.com), a biopharmaceutical company focused on treatments for hearing loss, announced today that it has successfully completed patient recruitment in the RESTORE study, an international, randomized, placebo-controlled, Phase 3...

Merck Announces FDA Breakthrough Therapy Designation for Investigational Therapy Tepotinib in Patients with Metastatic NSCLC with METex14 Skipping Alterations

- Investigational oral MET inhibitor has previously received SAKIGAKE 'fast-track' regulatory designation in Japan - MET exon 14 skipping alterations and MET amplifications are present in 3-5% of non-small cell lung cancer patients and correlate with...

Updated Results for Investigational Therapy Tepotinib Presented at WCLC 2019

- Results include progression-free survival and overall survival data from Phase Ib/II INSIGHT study - Phase II INSIGHT 2 study now open for enrollment for patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal...

Newly Published ROSacea COnsensus (ROSCO) Expert Recommendations Encourage Dermatologists to Upweight Burden-related Discussions, Aim For #Complete Clearance# of Symptoms and Consider Combination Therapy For Severe Patients

Experts also welcome upsurge in the adoption of a rosacea signs and symptoms ('phenotype') led approach in clinical practice and announce the launch of prototype clinical tools to support physicians to optimize rosacea management Published online in the...

Related Topics